BioMark™ DIAGNOSTIC SOLUTIONS INC

STONEGATE CAPITAL PARTNERS

August 18, 2021

Marco Rodriguez, CFA
marco@stonegateinc.com
214-987-4121

MARKET STATISTICS

Exchange / Symbol	CNSX: BUX
Price (CAD):	$0.22
Market Cap (CAD mm):	$10.4
Enterprise Value (CAD mm):	$9.9
Shares Outstanding (mm):	78.0
Float (%):	37.7%
Volume (3-month avg.):	82,463
52-week Range (CAD):	$0.07-$0.63
Industry:	Biotechnology

CONDENSED BALANCE SHEET

(CAD $mm, except per share data)

Balance Sheet Date:	03/31/2021
Cash:	$0.9
Cash/Share:	$0.01
Debt:	$0.1
Equity (Book Value):	$(0.1)
Equity/Share:	$(0.00)

CONDENSED INCOME STATEMENTS

(CAD $mm, except per share data)

FY – 3/31	Revenue	Net Loss	EPS
FY19	$0.0	$(0.5)	$(0.01)
FY20	$0.3	$(1.2)	$(0.02)
FY21	$0.0	$(1.1)	$(0.01)
FY21E	$0.0	$(1.1)	$(0.01)

LARGEST SHAREHOLDERS

Biomark Technologies, Inc.	41,004,167
Anonymous	5,500,000
Bux Investments Ltd.	2,380,000
Grg Consulting Ltd.	2,334,176
Guoyu Huang	1,992,024
G. Zhang	1,200,000
Rashid Bux	956,100

STOCK CHART



COMPANY DESCRIPTION

BioMark Diagnostics (CSE: BUX, OTCMKTS: BMKDF) is a Canadian Based company that develops proprietary, non-invasive, and accurate biotechnology and machine learning diagnostics solutions to detect early stage hard to detect and treat cancers. The company's cancer diagnostics technology is a metabolomics-liquid biopsy based diagnostic assay that allows for cancer detection, monitoring, and prognosis for treatment for cancer in its early stages, where approximately 90% of which can be cured. The company is currently focused on commercialization of its cancer diagnostic assay and detection systems and hopes to start distribution once clinical trials are completed and regulatory acceptance is obtained within the next 12-18 months.

COMPANY SUMMARY

- **Large and expanding market -** The global cancer diagnostic market is currently valued at approximately $170.0 billion and is estimated to grow and reach $280.6 billion by 2028 with a CAGR of 6.9%.
- **Developing a new paradigm in early lung cancer detection -** The company's metabolomics-diagnostics assay could become the standard in early detection of cancer due to better detection vs. traditional methods which could drastically help in the prognosis and treatment of cancers well before symptoms occur.
- **Non-invasive lead pan cancer assay with high specificity and sensitivity -** BioMark's initial assay is a highly accurate detection test using FDA-approved drugs for spermidine/spermine acetyltransferase (SSAT1), an enzyme which is elevated in the presence of numerous cancers.
- **Machine learning and artificial intelligence utilization -** BioMark is using state-of-the-art machine learning and artificial intelligence programs on its technology platform to complement its high-performance lung cancer panels.
- **Commercial partnership potential with hospitals –** The company believes that its proprietary plasma-based metabolic panel assay for early-stage lung cancer detection could be used within 1 year of approval in multiple hospitals.
- **Multiple revenue streams -** BioMark Diagnostics has the potential to generate multiple revenue streams from product supply sales, lab analysis, royalties, territorial and distribution licensing revenue.
- **Experienced management team -** Biomark Diagnostics has proven leadership with multiple years of experience in the biotechnology space. This global enterprise team consists of top scientists, engineers, regulatory, and medical professionals.
- **Valuation –** BioMark's market cap and enterprise value is $10.4M and $9.9M, respectively, which compares to median peer values at $57.9M and $47.9M, respectively. With a strong patent portfolio, large addressable markets, BioMark's projected revenue with a small market share penetration rate, and ongoing clinical trials, we would expect this discount to diminish.

BUSINESS OVERVIEW

BioMark Diagnostics is a cancer diagnostic company that is focused on the discovery and commercialization of novel biomarkers using metabolomics and incorporating machine learning algorithms. The company is developing proprietary, non-invasive, highly accurate solutions to cost-effectively detect cancer in the very early stages, where approximately 90% of cancers can be cured. The company is also developing diagnostics that can be used to increase the uptake of lung cancer screening using Low Dose CT, measuring a patient's response to treatment and for the ongoing monitoring of cancer survivors.

To this end, the company has developed a technology platform that can be used to detect early stages of cancer and for measuring a patient's response to treatment and for the ongoing surveillance for cancer recurrence. The company has designed a novel approach to cancer diagnostics using advanced liquid biopsy diagnostic technologies. The company's core products are the SSAT-Amantadine Assay and Metabolic Fingerprint Assays.

Exhibit 1: Liquid Biopsy Platform & Product Pipeline



Source: Company Reports

These proprietary, non-invasive, and accurate biotechnologies are currently undergoing clinical trials. The company's initial focus beyond a general cancer red alert tool is on diagnostics for lung cancer, with plans to expand into breast, pancreatic, thyroid, and glioblastoma cancers. The company hopes to start distribution once clinical trials are completed and regulatory acceptance is obtained.

Exhibit 2: Regulatory and Commercialization Timeline

Clinical Trials	Expected Timing
SSAT Assay Regulatory Submission	
Health Canada Submission	1Q21
Health Canada Approval Decision	2Q21
Commence Commercialization	4Q21
Lung Cancer – Monitoring Response to Chemo/Radio Treatment	
Peer Reviewed Publication	1Q21
Expand trial - ERB and Health Canada application submitted	1Q21
Commence larger multi-site trials	3Q21
Early Lung Cancer Detection	
Expand technology partnership	1Q21
Commence and complete large trial in Quebec	2Q21
Develop and beta test LDT (Lab Developed Test)	4Q21
Build lab infrastructure in Quebec	1Q22
Present data to regulatory agencies	2Q22
Introduce test / Commercialization with IUCPQ as beachhead	4Q22

Source: Company Reports

PAN CANCER ACETYL AMANTADINE ASSAY (SSAT 1)

One of BioMark's new innovative technologies is its BioMark SSAT1 Liquid Biopsy Assay. Here, the company's initial assay diagnoses cancer by utilizing metabolites that detect over-expression of the enzyme SSAT1, an enzyme with elevated levels in numerous cancers, using an FDA approved drug. Subjects ingest the FDA-approved drug amantadine, which then forms an enzyme-substrate complex. SSAT converts amantadine to a stable form which is then excreted from the cell. The stable form then passes through the kidneys and is excreted through urine.

Exhibit 3: SSAT Biochemistry – Polyamine Pathway



*Source: American Journal of Physiology - Endocrinology and Metabolism Published 4 June 2008 Vol. 294 no. 6

Source: Company Reports

The BioMark assay then detects a by-product of this SSAT1 reaction, resulting in a safe, stable, and effective indicator of healthy vs cancerous cells, making for the ideal biomarker and the potential for early detection of cancerous cells. The SSAT1 enzyme is highly expressed in many cancers, including lung, breast, prostate, and brain. There is also compelling scientific evidence to suggest that the SSAT1 Assay can be expanded for Glioblastoma (GBM), Pancreatic, Ovarian, Prostate and Head and Neck Cancers. The first diagnostic test kits will use urine with detection through LC/MS and ELISA kits.

Exhibit 4: BioMark metabolite approach vs traditional biomarkers approach



Source: Company Reports

The above image demonstrates the increased efficacy of the BioMark metabolite approach against the traditional biomarkers approach. With the BioMark metabolite approach, the cancerous cells are detected through the accumulated byproduct of the enzyme reaction, resulting in levels of detection many times better than traditional biomarkers. Meanwhile, the traditional biomarkers approach faces issues as limited levels of biomarkers create detection challenges. This approach is typically limited to detection at post-symptomatic stages, a much more lethal stage of cancer when compared to early stage.

The company is still in the clinical trials stage at this point in time with the SSAT1 Liquid Biopsy Assay. There are currently three ongoing clinical trials that are in varying stages of completion. First, *"Urinary Excretion of Acetylamantadine by Cancer Patients,"* by Principal Investigator Dr. Andrew Maksymiuk, MD, is in its Open stage and is in the process of final submission to Health Canada.

Next, Acetyl Amantadine as a Biomarker in patients with Glioblastoma, by Drs Marshall Pitz Cancer Care Manitoba and Don Miller Kleysen Institute of Advanced Medicine University of Manitoba

Finally, *"Excretion of Acetylamantadine (AA) by Lung Cancer Patients During a Chemotherapy Regimen,"* by Principal Investigator Dr. Andrew Maksymiuk, Co-Investigator: Dr. Daniel S. Sitar, and Co-Investigator Dr. Paramjit Tappia, is in its Open stage facing a mid-point assessment to establish proof of concept and patients still being enrolled with extended ethics approval. Obtained an NOL and sites to include IUCPQ under Dr. P. Joubert as PI.

Moreover, there are three clinical trials that have already concluded: *"Urinary Excretion of Acetylamantadine by Cancer Patients in Bangladesh"* by Principal Investigator: Prof. (Dr.) Parveen Shahida Akhtar, *"Food Effects on the Pharmacokinetics of Amantadine"* by Principal Investigator Prof. Zeneng Cheng, and *"Urinary Excretion of Acetylamantadine by Normal Healthy Volunteers"* by Principal Investigator: Dr. Bram Ramjiawan.

The assay targets a well-researched and understood metabolic pathway. BioMark is among a unique group of companies that uses a safe therapeutic agent for diagnostic indication. This assay (SSAT1) can be used as a non-invasive, cost-effective red alert tool for physicians globally.

BioMark has completed a comprehensive set of trials and is currently assembling a submission package to Health Canada for market approval for this test which physicians can use as an independent - pre-screening tool for cancer, specifically lung cancer, which will be combined with existing clinical assessment methods of screening for solid tumours, such as computed tomography (CT), magnetic resonance imaging (MRI), Xray and other molecular tests

METABOLIC FINGERPRINT ASSAY

In addition to the SSAT-Amantadine cancer assay, the company has developed metabolic fingerprint assays which help in determining the location and stage of cancer in a non-invasive manner. Metabolic fingerprints are unique chemical patterns and are determined by the biochemical state of the cell. Importantly, the fingerprint assays follow the same principles as the SSAT-Amantadine assay allowing for highly accurate detection.

Metabolic patterns are consistent in the human population, similar to body temperature. In cancer cells, biochemical pathways are disrupted due to mutations or overly active/expressed enzymes in the proteins. Dysfunctional proteins in a pathway are often related to cancers and can cause an imbalance in metabolite concentrations that are different from healthy cells. which can then be detected as these patterns are common in populations with certain types of cancers.

BioMark's focus is on the polyamine pathway due to its connection to many types of cancer. But the company has defined and validated the preliminary fingerprint for lung cancer and are in the process of defining the fingerprint for breast cancer.

BIOMARK LIQUID BIOPSY METABOLIC PANEL ASSAYS

The company has also developed and validated BioMark Liquid Biopsy Metabolic Panel Assays, a new form of high-powered metabolic panel assay for early diagnosis of Lung Cancer. This performance panel assay has demonstrated through clinical trials superior detection capabilities for early stage I and II lung cancers using urine and plasma. In the 2nd quarter of 2019, a 260-patient retrospective lung cancer trial discovered and validated this metabolite panel plasma assay for early-stage lung cancer (I and II) with ROC > 0.9, an excellent rating with respect to the ability to diagnose patients with and without the disease or condition based on the test. These results were published in Cancers Journal (Aug 2019 and March 2020). According to the company, this performance panel assay is a major breakthrough in Lung Cancer diagnostics and strategically positions the company in a great position in the high-risk lung cancer screening market, which currently uses low dose CT (LDCT) scans.

Exhibit 5: 5 Year Relative Survival Rates (%)

STAGE	LUNG (NSCLC)	BREAST	PANCREATIC
1A	92	100	37
1B	68		
2A	60	93	12
2B	53		
3A	36	72	3
3B	26		
4	10	22	

Source: Company Reports

This high-performance panel assay has clinically demonstrated superior detection capabilities for early stage I / II (NSCLC) Lung Cancers using urine and plasma. According to the company, this is a major breakthrough in Lung Cancer diagnostics and strategically positions the company in a vintage position for high-risk lung cancer screening market which currently uses low dose CT scans (LDCT). ML is being incorporated in the analysis of the assay.

The market opportunity for lung cancer is large. Lung cancer has been the most common cancer globally, accounts for 1 in 5 of all cancer deaths, and more than 2/3rds of patients are diagnosed with lung cancer at a later stage when their survival rates are lower. The company is targeting lung cancer screening to complement LDCT scans and estimates a population size of 16M in the US and 1.4M in Canada. The company notes that its lung cancer metabolic fingerprint assay is cost effective and can potentially reduce false positives and negatives associated with LDCT scan. Furthermore, the assay can be used as a routine test and can be used to follow patients with abnormalities (nodules) that are difficult to confirm using CT scans.

CURRENT RESEARCH

BioMark states that there is compelling scientific evidence to suggest that the SSAT1 Assay can be expanded for Glioblastoma (GBM), Pancreatic, Prostate, and Head and Neck Cancers. In fact, the company will be pursuing cancer research and clinical trials for all the aforementioned types of cancers.

For Glioblastomas, CancerCare Manitoba ethics obtained approval for the protocol and newly diagnosed patients are currently being treated. This treatment uses both the SSAT1 assay as well as new panels. Clinical trial sites are currently being expanded in North America at University of Maryland and Johns Hopkins.

For Breast Cancer, the company has identified and validated several putative markers and is currently awaiting analysis of samples following a larger cohort trial. Results are expected by end of September 2021.

For Head and Neck cancers, the company is in discussion with a major European center (Brescia University) to develop a comprehensive Omics panel of markers for a high relapse cancer cohort. The protocol is being modified to potentially extend trials to additional North American healthcare and research facilities pending Health Canada and ethics approvals. The trials in Italy began 3 months ago and recruitment has been very promising. The trail is targeting a 200-patient cohort.

MACHINE/DEEP LEARNING

The company has also started utilizing machine and deep learning techniques alongside its lung cancer assays. These models will allow BioMark to incorporate more patient clinical data models which will then allow for greater accuracy in prediction of trends in its network, bringing tangible benefits to clinicians. After development of these technologies, BioMark hopes to embed this application into its own technology platform. With help from scientists from the University of Alberta and IUCPQ, BioMark hopes to incorporate both digital and physical markers alongside AI in order to detect lung cancer.

Unlike most diagnostic companies, BioMark is in a unique position to collect and analyze data from its targeted cancer consumer testing. Although metabolomic testing is not as popular as DNA testing, BioMark intends to become a leader in this space. Using data collected from plasma/urinalysis biofluids, the company is developing a cloud platform that will:

- Continually validate the SSAT-Amantadine frontline assay.
- Continually improve the metabolic fingerprint maps for each cancer (population medians).
- Provide personalized patient information to physicians allowing for improved prognosis and treatment options integrating ML, radiomics and new risk models to amplify the power of its diagnostic assays
- Provide a platform for more engaging patient navigation system.
- Selectively include other Omics test.
- Assess risk and modify behavior for at risk population

These features would allow for support and monitoring on a 24/7 basis which will be ideal for a DTC service model. In addition to the data gathered for future decision making, this would be a major revenue stream for the company.

BioMark responded to operational issues caused by the COVID-19 pandemic by repurposing its Raman Spectrometer to assess the probability of detecting the COVID virus. Additionally, the company in 2020 partnered with Stream.ML and Merogenomics to form Bio-Stream Diagnostics, Inc., a company focused on providing low cost and accurate COVID-19 detection in under 30 seconds. Using surface-enhanced Raman spectroscopy, biosensors and machine learning algorithms, the company hopes to build a full testing system pipeline starting from disposable sample collection to software model execution.

The company also has future plans to expand the test to include other pathogens. Bio-Stream has the option to license its assays to CLIA-certified laboratories across the United States.

MARKET OPPORTUNITY

The target market is large and expanding. According to the Allied Market Research Report *World Noninvasive Cancer Diagnostics and Technologies Market - Opportunities and Forecasts, 2021-2028*, the global cancer diagnostic market is currently valued at approximately $170 billion and is estimated to grow to reach $280.59 billion by 2028 with a CAGR of 6.9%. Many M&A and venture capital transactions have occurred in the space, including but not limited to:

- Agilent 's acquisition of Resolution Bioscience for $550 million and closing up to an additional $145 million
- Roche's acquisition of GenMark for $1.8 billion
- InterVenn Biosciences raised $201 million funding for its AI platform from Softbank, others
- PathAI's diagnostics portfolio acquisition of Poplar
- Strata Oncology raised $90 million from Pfizer, Merck, and others

BioMark's DTC offering is also competitively positioned to take advantage of a large and rapidly expanding market. According to Transparency Market Research's 2021 Report *Direct to Consumer Laboratory Testing Market*, the global direct-to-consumer laboratory testing market was valued at $2.4 billion in 2020 and is expected to expand at a CAGR of 26% from 2021 to 2031.

Exhibit 6: Global Next Gen Cancer Market Projection 2022



Source: Company Reports

Additionally, the rates of global cancer are increasing over the foreseeable future. Currently, cancer accounts for 1 in 6 deaths worldwide and is the second most common cause of death in the US (behind heart disease). By 2040, the number of cancer cases worldwide is expected to reach 27.5 million and the number of deaths is expected to reach 16.3 million solely due to growth and aging of the population. With the large burden that cancer will have on future global populations and infrastructure, innovative biotechnology solutions are likely necessary to curb these issues.

BioMark's goal in its first 24 months of product rollout is to capture 2-5% of the US next-generation cancer diagnostics market (about $40 million - $90 million), allowing for rapid growth and market positioning as the standard of care for routine physicals.

Risks

Issues in product introduction/sales - BioMark does not currently generate significant revenues on its product lines. Failure to generate future sales on its new products will have a significant and adverse effect on the company.

Issues with clinical research - BioMark is currently involved in clinical research related to its core technologies and regulatory submissions. Regulatory denials, negative clinical trials, and significant delays could adversely affect the company's revenues.

Market entrants/industry evolution - Additional market entrants could impact the competitive position of BioMark, possibly having an adverse impact on sales. Additionally, new detection and screening technologies which incorporate big data could negatively impact BioMark's future revenues and profitability.

Limited operating history and history of losses - Biomark Diagnostics has a limited operating history, making it difficult to evaluate the business. Since its inception, the company has had 1.035 million dollars in total liabilities as of 2021 and is currently operating with a negative cash flow. As the company is relatively new, losses and negative cash flows are expected to continue.

Covid19-related research slowdowns - COVID-19 has had operational and commercial impacts on BioMark. The application for Translational Research Partnerships Program with Cancer Research Society and Dr. Phillipe Joubert from IUCPQ in Quebec was halted due to COVID-19. Glioblastoma studies at CancerCare Manitoba were delayed in being granted ethics approval, and BioMark was unable to assess treatment responses and present at conventions due to COVID-19 related suspensions. If restrictions continue, BioMark's cancer-related operations will continue to be negatively impacted.

Liquidity risk - The company has historically addressed liquidity through equity financing obtained through sale of common shares. As the company currently does not currently generate any revenue, it will likely have to raise additional capital to continue to finance its activities. There is no assurance that the company will be able to continue to obtain financing on similar terms, or at all, and purchasing the company's common shares is fairly high risk which could impact the company's ability to attract investors. If the company is unable to raise capital, its future business operations will be substantially impacted.

VALUATION

Below we outline comparable companies to help frame valuation of BioMark. The peer group contains other biotech companies that are at the similar stages and size as BioMark.

Exhibit 7: Comparable Company Analysis

Comparative Analysis
(all figures in $CAD M, expect per share information)

Company Name	Symbol	Price (1)	Mrkt Cap	EV	EV/Sales (2) 2020	2021E	2022E
VentriPoint Diagnostics Ltd.	TSXV:VPT	$ 0.37	$ 50.2	$ 47.9	NM	N/A	N/A
SQI Diagnostics Inc.	TSXV:SQD	$ 0.16	$ 58.0	$ 59.1	59.6x	N/A	N/A
Telo Genomics Corp.	TSXV:TELO	$ 0.45	$ 25.6	$ 23.7	N/A	N/A	N/A
Biocept, Inc.	NASDAQ:BIOC	$ 4.32	$ 57.9	$ 47.9	1.8x	0.9x	1.5x
Oncimmune Holdings plc	AIM:ONC	$ 3.31	$ 229.1	$ 241.6	273.6x	24.6x	11.4x
	Average		**$ 84.1**	**$ 84.0**	**111.6x**	**12.7x**	**6.5x**
	Median		**$ 57.9**	**$ 47.9**	**59.6x**	**12.7x**	**6.5x**
BioMark Diagnostics Inc.	CNSX: BUX	$ 0.22	$ 10.4	$ 9.9	N/A	N/A	N/A

(1) Previous day's closing price
(2) Estimates are from Capital IQ

Source: Capital IQ, Stonegate Capital Partners

As can been seen above, BioMark trades at a considerable discount to its peer's market capitalization and enterprise values. With a strong patent portfolio, large addressable markets, BioMark's projected revenue with a small market share penetration rate, and ongoing clinical trials, we would expect this discount to diminish.

BALANCE SHEET

Biomark Diagnostics
Consolidated Balance Sheets (CAD$ Ms)
Fiscal Year: March

ASSETS	FY 2020	FY 2021
Assets		
Cash and Cash Equivalents	0.612	0.878
Accounts Receivables	0.016	0.027
Prepaid Expenses	-	0.018
Total Current Assets	0.628	0.923
Right of Use Assets	0.007	0.027
Equipment and Tools	0.002	-
Long-term Investments	-	0.003
Total Assets	**$0.637**	**$0.953**
LIABILITIES AND SHAREHOLDERS' EQUITY		
Current Liabilities		
Accounts Payable and Accrued Liabilities	0.112	0.027
Lease Liability	0.009	0.010
Due to a Related Party	0.956	0.886
Total Current Liabilities	**1.076**	**0.922**
Long Term Government Loan	-	0.092
Long-term Lease Liability	-	0.018
Total Long Term Liabilities	**-**	**0.110**
Shareholders' Deficiency		
Common Stock - Par Value	5.433	6.876
Additional Paid in Capital	1.769	1.632
Deficit	(7.496)	(8.591)
Subscribed Share Capital - Common	(0.145)	0.003
Total Stockholders Equity	**(0.439)**	**(0.079)**
Total Liabilities and Shareholders' Deficiency	**$0.637**	**$0.953**

Source: Company Reports, Stonegate Capital Partners

INCOME STATEMENT

Biomark Diagnostics
Consolidated Statements of Income (in CAD$Ms, except per share amounts)
Fiscal Year: March

	FY 2019	FY 2020	FY 2021	FY 2022E
Revenue	$ -	$ 0.263	$ -	$ -
Expenses:				
Consulting Fees	0.330	0.392	0.385	0.400
Professional Fees	0.082	-	-	-
Depreciation on Right-of-use Assets	-	0.012	0.011	0.001
Depreciation on Equipment and Tools	-	-	0.002	0.002
Filing and Transfer Agent Fees	0.019	0.024	0.066	0.070
Office and Miscellaneous	0.036	0.032	0.020	0.025
Legal & Professional Fees	-	0.089	0.088	0.090
Interest and Bank Charges	-	0.002	0.004	0.003
Research and Other	0.056	0.042	0.118	0.120
Share-based Compensation (recovery)	0.002	0.856	0.395	0.400
Travel	0.021	0.023	0.007	0.015
Total Operating Expenses	**0.546**	**1.472**	**1.098**	**1.126**
Other (income) loss:	-	-	-	-
Currency Translation (Gain) Loss	-	(0.009)	0.010	-
(Gain)/loss on Settlement of Debt	-	0.015	(0.003)	-
Government Grants	-	-	(0.011)	-
Interest Income	-	(0.000)	(0.000)	-
Total other (income) loss	**-**	**0.006**	**(0.004)**	**-**
Net Loss	**(0.546)**	**(1.215)**	**(1.094)**	**(1.126)**
Basic & Diluted Loss Per Share	$ (0.01)	$ (0.02)	$ (0.02)	$ (0.01)
WTD Avg Shares Outstanding	65.915	71.296	73.305	75.871

Source: Company Reports, Stonegate Capital Partners estimates

IN THE NEWS

June 29, 2021 - Biomark to Expand Treatment Response Trial to Advanced Lung Cancer Patients Receiving Immunotherapy.

June 1, 2021 - BioMark Receives $825K Grant to Develop Its Liquid Biopsy Assay for Lung Cancer Screening.

May 31, 2021 - BioMark Announces Change of Auditor.

April 29, 2021 - Biomark to Open a Diagnostic Laboratory in Quebec.

April 21, 2021 - BioMark Announces Exercise of Warrants and Gain DTC Eligibility for Its Common Shares.

March 16, 2021 - Biomark's Collaborator Receives Funding to Validate Its Biomarker Panel for the Early Detection of Lung Cancer.

March 2, 2021 - BioMark Grants Options.

February 16, 2021 - BioMark and Phytronix Technologies Inc. Enter into a Collaborative Research and Development Agreement.

February 8, 2021 - BioMark Diagnostics Targets Response to Treatment Application with Its Liquid Biopsy Platform.

January 11, 2021 - Alfred Berkeley Joins BioMark's Advisory Team.

December 7, 2020 - BioMark Retains Questrade, Inc. to Provide Market-Making Services.

September 23, 2020 - BioMark Scientific Advisor Dr. Donald Miller to Present at the Delaware Valley Drug Metabolism Discussion Group.

September 16, 2020 - BioMark Appoints Dr. Jean-Francois Haince as Strategic Advisor to Guide Its Expansion into Quebec.

September 14, 2020 - BioMark Team Invited for Full Application for Sparks Grant Competition.

August 27, 2020 - BioMark Team Secures Health Canada letter of No Objection for its Glioblastoma Clinical Trial.

August 13, 2020 - BioMark Diagnostics Expands Research Development in Quebec.

July 21, 2020 – BioMark's Affiliated Company, Bio-Stream Diagnostics Inc. Announces Partnership with Qatar University ML Team for Development of COVID-19 Testing.

CORPORATE GOVERNANCE

Rashid Ahmed Bux, MBA - Founder, President, Chief Executive Officer

Mr. Bux is a veteran of the healthcare industry, bringing leadership, strategy, and decades of experience to the ever-changing landscape of biotechnology organizations. He has served in the C-suite of multiple healthcare companies, including roles as the President of Arhaus LLC, CEO and Founder of Biomark Technologies, Inc., COO of KKT Orthopedic Spine Center, and COO Optima Health Solutions. He holds 7 patents and has published in several peer reviewed journals. Mr. Bux received an undergraduate degree from Miami University and an MBA from the University of Western Ontario.

Dr. Jeff Haince, Ph.D. - Chief Scientific Officer and GM
Dr. Haince holds a PHD in Cellular and Molecular Biology from the Faculty of Medicine at Université Laval. In his over 15 years of experience in cancer research, he has authored over 20 peer-reviewed scientific publications. Prior to his role at Biomark Diagnostics, he was responsible for new molecular diagnostic tests at DiagnoCure from 2007 to 2015. He currently also manages a team of experts at the Scientific Innovation Powerhouse, sits on the Research and Innovation Committee at the l'Institut National du Sport du Québec.

Other Members:

Dr. Bram Ramjiawan - *Clinical Trial and Regulatory Expert*

Brian Cheng - *CTO*

Gina Huang, MBA - *CFO and Project Director*

Dr. Daniel Sitar – *Principal Scientific Advisor / Professor Emeritus, University of Manitoba*

Dr. David Wishart – *Professor, Depts. of Computer Science and Biological Sciences, University of Alberta*

Dr. Myron L. Weisfeldt – *M.D., University Distinguished Service Professor, Professor of Medicine, The Johns Hopkins Hospital*

Dr. Andrew Maksymiuk – *Oncologist; Cancer Care Manitoba*

Dr. Reuven Gordon – *Professor, Canadian Research Chair in Nanoplasmonics, University of Victoria*

Dr. Paramjit Tappia – *Scientific and Clinical Researcher, St. Boniface Research Centre*

Dr. John Yoo – *Clinical Oncologist; Co-Chair CancerCare Ontario Head and Neck; Professor Dept. of Oncology Schulich School of Medicine & Dentistry, Western Ontario*

Dr. Donald Miller – *Professor, Department of Pharmacology and Therapeutics University of Manitoba*

Dr. David Chen – *Professor, Dept. of Chemistry, University of British Columbia*

Dr. Horacio Bach – *PhD, Antibody Engineering UBC*

Alfred Berkeley – *Strategic and financial advisor*

IMPORTANT DISCLOSURES AND DISCLAIMERS

The following disclosures are related to Stonegate Capital Partners (SCP) research reports.

The information used for the creation of this report has been obtained from sources we considered to be reliable, but we can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice and SCP does not undertake to advise you of any such changes. In preparing this research report, SCP analysts obtain information from a variety of sources, including to but not limited to, the issuing Company, a variety of outside sources, public filings, the principals of SCP and outside consultants. SCP and its analyst may engage outside contractors with the preparation of this report. The information contained in this report by the SCP analyst is believed to be factual, but we can neither guarantee nor represent the completeness or accuracy of the information herewith. While SCP endeavors to update the information contained herein on a reasonable basis, there may be regulatory, compliance, or other reasons that prevent us from doing so. The opinions or information expressed are believed to be accurate as of the date of this report; no subsequent publication or distribution of this report shall mean or imply that any such opinions or information remains current at any time after the date of this report. Reproduction or redistribution of this report without the expressed written consent of SCP is prohibited. Additional information on any securities mentioned is available on request. SCP does not rate the securities covered in its research. SCP does not have, nor has previously had, a rating for any securities of the Company. SCP does not have a price target for any securities of the Company.

Recipients of this report who are not market professionals or institutional investors should seek the advice of their independent financial advisor prior to making any investment decision based on this report or for any necessary explanation of its contents. Because the objectives of individual clients may vary, this report is not to be construed as an offer or the solicitation of an offer to sell or buy the securities herein mentioned. This report is the independent work of SCP and is not to be construed as having been issued by, or in any way endorsed or guaranteed by, any issuing companies of the securities mentioned herein.

SCP does not provide, nor has it received compensation for investment banking services on the securities covered in this report. SCP does not expect to receive compensation for investment banking services on the securities covered in this report. SCP has a non-exclusive Advisory Services agreement to provide research coverage, retail and institutional awareness, and overall Investor Relations support and for which it is compensated $2,500 per month. SCP's equity affiliate, Stonegate Capital Markets (SCM) - member FINRA/SIPC - may seek to provide investment banking services on the securities covered in this report for which it could be compensated.

SCP Analysts are restricted from holding or trading securities in the issuers which they cover. Research Analyst and/or a member of the Analyst's household do not own shares of this security. Research Analyst, employees of SCP, and/or a member of the Analyst's household do not serve as an officer, director, or advisory board member of the Company. SCP and SCM do not make a market in any security, nor do they act as dealers in securities.

SCP Analysts are paid in part based on the overall profitability of SCP and SCM. Such profitability is derived from a variety of sources and includes payments received from issuers of securities covered by SCP for services described above. No part of Analyst compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in any report or article. This security is eligible for sale in one or more states. This security may be subject to the Securities and Exchange Commission's Penny Stock Rules, which may set forth sales practice requirements for certain low-priced securities.

CONTACT INFORMATION

Investor Relations
BioMark Diagnostics Inc.
3851 Shell Road Suite 130
Richmond, BC V6X 2W2
Phone: 604-370-0779
www.biomarkdiagnostics.com

Investor Relations
Stonegate Capital Partners
8201 Preston Rd.-Suite 325
Dallas, Texas 75225
Phone: 214-987-4121
www.stonegateinc.com